We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
-7.7%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$211M
AUM Growth
+$27.6M
(+15%)
Cap. Flow
+$53.8M
Cap. Flow
% of AUM
25.48%
Top 10 Holdings %
Top 10 Hldgs %
55.57%
Holding
55
New
15
Increased
12
Reduced
13
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$11.5M |
| 2 |
ADC Therapeutics
ADCT
|
+$10.3M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$9.22M |
| 4 |
KZR
Kezar Life Sciences
KZR
|
+$8.36M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$8.32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALBO
Albireo Pharma Inc
ALBO
|
+$10.5M |
| 2 |
TriNet
TNET
|
+$5.29M |
| 3 |
Health Catalyst
HCAT
|
+$3.7M |
| 4 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$3.68M |
| 5 |
Aldeyra Therapeutics
ALDX
|
+$3.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.96% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$458M
| $21.7M | 10.27% |
447,092
+117,092
| +35% | +$6.19M |
|
|
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $14.5M | 6.88% |
375,500
-89,500
| -19% | -$3.68M |
|
3
Mirum Pharmaceuticals
MIRM
$6.89B
| $13.6M | 6.47% |
567,826
+259,050
| +84% | +$5.9M |
|
4
Humana
HUM
$46.7B
| $11.7M | 5.52% |
24,000
+6,747
| +39% | +$3.34M |
|
|
5
Centene
CNC
$31.3B
| $10.2M | 4.84% |
+161,404
| New | +$11.5M |
|
|
KZR
6
DELISTED
Kezar Life Sciences
KZR
| $10M | 4.75% |
320,000
+144,557
| +82% | +$8.36M |
|
|
7
BioCryst Pharmaceuticals
BCRX
$2.37B
| $8.96M | 4.25% |
1,074,593
+957,861
| +821% | +$9.22M |
|
8
Alkermes
ALKS
$8.82B
| $8.91M | 4.23% |
316,165
-25,356
| -7% | -$691K |
|
|
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $8.84M | 4.19% |
81,035
-8,965
| -10% | -$991K |
|
10
Oric Pharmaceuticals
ORIC
$1.25B
| $8.81M | 4.17% |
1,545,000
+365,000
| +31% | +$1.91M |
|
|
11
Neurocrine Biosciences
NBIX
$17.7B
| $8.1M | 3.84% |
+80,000
| New | +$8.32M |
|
12
MeiraGTx Holdings
MGTX
$1.09B
| $7.7M | 3.65% |
1,488,917
-144,629
| -9% | -$1M |
|
|
13
ADC Therapeutics
ADCT
$146M
| $6.35M | 3.01% |
3,257,360
+2,794,050
| +603% | +$10.3M |
|
14
Arcturus Therapeutics
ARCT
$157M
| $6.11M | 2.9% |
+255,000
| New | +$4.58M |
|
15
Shattuck Labs
STTK
$710M
| $5.94M | 2.82% |
2,021,668
-91,825
| -4% | -$325K |
|
16
AbCellera Biologics
ABCL
$1.62B
| $5.68M | 2.69% |
753,528
+430,774
| +133% | +$3.91M |
|
17
UnitedHealth
UNH
$382B
| $5.17M | 2.45% |
10,935
+5,935
| +119% | +$2.86M |
|
18
Option Care Health
OPCH
$3.4B
| $4.92M | 2.33% |
154,900
+2
| +0% | +$60 |
|
19
QuidelOrtho
QDEL
$1.09B
| $4.31M | 2.04% |
48,355
-1,645
| -3% | -$143K |
|
20
Cue Biopharma
CUE
$135M
| $4.11M | 1.95% |
38,395
-22,955
| -37% | -$2.19M |
|
21
Johnson & Johnson
JNJ
$635B
| $3.91M | 1.85% |
+25,210
| New | +$4.07M |
|
|
NARI
22
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $3.83M | 1.82% |
+62,081
| New | +$3.72M |
|
|
23
Aldeyra Therapeutics
ALDX
$91.7M
| $3.81M | 1.81% |
383,447
-475,262
| -55% | -$3.36M |
|
24
Pacira BioSciences
PCRX
$1.02B
| $3.72M | 1.76% |
+91,123
| New | +$3.63M |
|
|
LBPH
25
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $3.61M | 1.71% |
+900,600
| New | +$4.4M |
|
Similar funds
PL
BFC
DCM
SAM
CBB
AIG
FFWA
CIP
Prosight Management's Q1 2023 Portfolio in Review
As of Q1 2023, Prosight Management held 55 positions worth $211M, up 15% from $183M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Prosight Management deployed $53.8M of net new capital in Q1 2023, opening 15 new positions and adding to 12 existing holdings. Its largest new stake was Centene: 161,404 shares worth $10.2M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $3.68M trimmed.
- Prosight Management's largest Q1 2023 buy was Centene: 161,404 shares worth $10.2M.
- Prosight Management added most to ADC Therapeutics in Q1 2023, an estimated $10.3M increase.
- Prosight Management's biggest Q1 2023 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $3.68M.
- Prosight Management fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $10.5M.
- Prosight Management's ten largest holdings make up 56% of its $211M portfolio in Q1 2023.
- Prosight Management opened 15 new positions and closed 14 in Q1 2023.
- Prosight Management's portfolio value rose 15% quarter-over-quarter to $211M.
Based on Prosight Management's 13F filing for Q1 2023, filed 12 May 2023.